FDA Grants Priority Review to Tucatinib for HER2-Positive Breast Cancer Treatment

The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.

Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news